BERKELEY HEIGHTS, N.J., June 29, 2011 (GLOBE NEWSWIRE) -- Genta Incorporated (OTCBB:GNTA) provided a comprehensive update of its clinical trials programs with tesetaxel, the Company's lead investigational drug. The information was presented by Genta's Chairman and Chief Executive Officer, Dr. Raymond P. Warrell, Jr., at the 2011 BIO International Business Forum in Washington, D.C., the world's premier partnering meeting.
